Ignite Creation Date:
2025-12-24 @ 4:30 PM
Ignite Modification Date:
2026-02-04 @ 4:01 PM
Study NCT ID:
NCT05104866
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-14
First Post:
2021-10-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Breast Cancer | View |
| None | HR positive | View |
| None | Hormone Receptor positive | View |
| None | ER positive | View |
| None | PR positive | View |
| None | HER2 negative | View |
| None | Inoperable | View |
| None | Metastatic | View |
| None | Datopotamab Deruxtecan | View |
| None | Dato-DXd | View |
| None | DS1062 | View |
| None | DS1062a | View |
| None | Capecitabine | View |
| None | Eribulin | View |
| None | Gemcitabine | View |
| None | Vinorelbine | View |
| None | TROP2 | View |
| None | Antibody Drug Conjugate | View |
| None | ADC | View |